Tests moxifloxacin antibiotic to prevent flare-ups in bronchiectasis
Tests intermittent moxifloxacin antibiotic against standard care in adults with bronchiectasis.
Plain-language title generated from the registry record
Registry title: Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients
Key facts
- Where
- Asyut, EgyptSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-cystic fibrosis bronchiectasis who had at least 2 flare-ups in the past 12 months. It tests long-term, on-and-off moxifloxacin against standard care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Bronchiectasis not caused by cystic fibrosis, confirmed by a high-resolution CT scan. At least 2 exacerbations (flare-ups) in the previous 12 months.
- Earlier treatment
- Cannot have used long-term suppressive antibiotics for bronchiectasis in the past 3 months.
Main reasons for not taking part
- Bronchiectasis related to cystic fibrosis
- Known allergy or contraindication to fluoroquinolones, including moxifloxacin
- Severe liver problems or severe kidney problems (eGFR <30 mL/min/1.73 m²)
- Pregnancy or breastfeeding
- History of significant QT prolongation or arrhythmia, or use of QT-prolonging drugs
Read by machine on 12 November 2026.
Where in Egypt
- Assiut University hospitalAsyut, EgyptContact: Montaser Gamal Elddin, LecturerNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assiut University
- Trial code
- NCT07274020
- Record updated
- 10 December 2025
- Original description
Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage. Frequent exacerbations are associated with increased morbidity, accelerated lung function decline, and reduced quality of life. Preventing exacerbations is a key therapeutic goal. Moxifloxacin, a fluoroquinolone antibiotic with broad-spectrum activity, may play a role in intermittent eradication therapy to reduce bacterial load, achieve microbiological clearance, and minimize exacerbation frequency.Read full original descriptionShow less
Effectiveness and Safety of Long-Term Intermittent Moxifloxacin Eradication Therapy in Non-Cystic Fibrosis Bronchiectasis: A 12-Month Randomized Controlled Trial
Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage. Frequent exacerbations are associated with increased morbidity, accelerated lung function decline, and reduced quality of life. Preventing exacerbations is a key therapeutic goal. Moxifloxacin, a fluoroquinolone antibiotic with broad-spectrum activity, may play a role in intermittent eradication therapy to reduce bacterial load, achieve microbiological clearance, and minimize exacerbation frequency.
This randomized controlled trial will evaluate the effectiveness and safety of long-term intermittent moxifloxacin therapy compared with standard care in patients with non-cystic fibrosis bronchiectasis.
Inclusion: Adults ≥18 years of age; Confirmed diagnosis of non-cystic fibrosis bronchiectasis by high-resolution CT (HRCT); History of ≥2 bronchiectasis exacerbations in the previous 12 months.
Exclusion: Known hypersensitivity or contraindication to fluoroquinolones (including moxifloxacin); Severe hepatic impairment or severe renal impairment (eGFR <30 mL/min/1.73 m²); History of significant QT prolongation, arrhythmia, or concurrent use of QT-prolonging drugs; Diagnosis of cystic fibrosis-related bronchiectasis; Pregnancy or breastfeeding; Use of long-term suppressive antibiotics for bronchiectasis in the past 3 months.